Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from GSK Plc

3 Pharma Stocks to Capitalize on With Potential Upside

The pharma industry’s prospects look bright, thanks to rising demand for innovative drugs. Thus, pharma stocks with potential upside, like GSK plc (GSK), Johnson & Johnson (JNJ), and Bristol-Myers Squibb Company (BMY), could be wise investments to capitalize on right now. Read on….

StockNews.com

3 Promising Pharma Stocks to Keep on Your Radar

The pharma industry’s prospects look bright, thanks to rising demand for generic and innovative drugs and technological advancements. Hence, adding fundamentally strong pharma stocks Astellas Pharma (ALPMY), Sanofi (SNY), and GSK (GSK) to one’s watchlist could be wise. Keep reading.

StockNews.com

3 Pharma Stocks for Value Investors

The aging global population and the growing demand for drugs and therapies to treat chronic diseases are boosting the long-term prospects of the pharmaceutical industry. Amid this backdrop, value investors could consider buying fundamentally strong pharma stocks GSK plc (GSK), Horizon Therapeutics (HZNP), and Neurocrine Biosciences (NBIX), as they are…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Stocks Investors Are Chasing for Value

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

StockNews.com

Gonorrhea shot gets FDA fast track as resistant cases multiply

GSK Plc’s experimental gonorrhea vaccine got fast-track designation from U.S. regulators, putting the shot in position to become the first preventive for a common, often-undetected infection that’s gaining resistance to treatment.

Tribune News Service

3 Top-Rated Companies to Buy Today

Amid the Fed’s monetary policy tightening and the recent financial sector turmoil, fears of an economic slowdown have soared, which in turn induced market volatility. Given this backdrop, quality stocks Comcast Corp. (CMCSA), Medtronic (MDT), and GSK plc (GSK) might be solid buys today. Read on….

StockNews.com

3 Pharma Stocks to Buy in 2023 and Hold for Decades

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Must Have Pharma Stocks in January 2023

Rising rates of chronic diseases, an aging population, and increasing healthcare spending should drive the pharma industry’s growth in the upcoming years. Moreover, pharma companies perform steadily regardless of economic conditions due to the inelastic demand for their products. Therefore, it could be wise to invest in fundamentally strong pharma…

StockNews.com

3 Upgraded Stocks to Consider Buying This Week

The red-hot inflation is increasing the odds of continued rate hikes by the Fed. Since the market is expected to remain under pressure on recession fears, it could be wise to invest in fundamentally sound stocks Comcast Corporation (CMCSA), GSK (GSK), and Masonite International (DOOR), which have been recently upgraded…

StockNews.com

iPhone 14 Popular In China?, Netflix May Lose Comics, Elon Musk's Starlink Slows, Byron Allen Faces $10B Lawsuit And More Top Financial Media Stories Monday, Sept. 26

Bloomberg

Benzinga

5 “Strong Buy” Health Care Stocks to Buy This Week

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

StockNews.com

3 Health Care Stock Under $50 You Can Buy Today

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…

StockNews.com

Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

Benzinga

Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK

Ideaya Biosciences Inc (NASDAQ:IDYA) has selected a potential first-in-class Pol Theta Helicase development candidate, a small molecule inhibitor of the helicase domain of DNA Polymerase Theta. Ideaya is collaborating with GSK plc (NYSE:GSK) on IND-enabling studies to support the evaluation of the Pol Theta Helicase candidate in combination with niraparib, GSK's PARP inhibitor, in tumors with…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

GSK Shares Encouraging Data From Chronic Hepatitis B Candidate

GSK plc (NYSE:GSK) announced promising interim results from the B-Clear phase 2b trial of bepirovirsen in people with chronic hepatitis B (CHB). The data showed that bepirovirsen reduced hepatitis B surface antigen (HBsAg) levels and hepatitis B virus (HBV) DNA after 24 weeks of treatment. In the group of 227 patients on standard…

Benzinga

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Sanofi SA (NASDAQ:SNY) and GSK plc (NYSE:GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement. The bivalent vaccine targets the…

Benzinga

Antibiotic Makers Adopt Their Own Environmental Safeguard Standards

The AMR Industry Alliance, a life-sciences coalition set up to provide sustainable solutions to curb antimicrobial resistance (AMR), is adopting its standards limiting toxic emissions. The Alliance published its Antibiotic Manufacturing Standard: Minimizing the risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from manufacturing human antibiotics. The…

Benzinga

GSK Shows Positive Pivotal Phase III Data For Its RSV Vaccine Candidate

GSK plc (NYSE:GSK) intends to engage with regulators immediately after reporting positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial, it anticipates regulatory submissions in the second half of 2022. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off

Pfizer Inc. (NYSE:PFE) intends to sell its 32% investment in Haleon, a consumer health joint venture with GSK plc (NYSE:GSK), after the business is spun out as an independent listed company in July, reported Reuters. Pfizer had previously indicated that it might seek to sell its stake in Haleon, a consumer health company and…

1 2

People

Elon Musk

28,335 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.